- Drug name
- Influenza A virus whole
- influenza a virus
- Influenza A Virus
- FDA ingredient codes (UNII)
Related records
Trials (22)
- A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® Vaccine
- A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)
- Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children
- B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
- Comparison of 4 Influenza Vaccines in Seniors
- Effects of Aging on Primary and Secondary Vaccine Responses
- Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)
- Gene Expression Profiles in Muscle After Immunisation
- Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years
- Immunogenicity & Safety Study of Fluviral® (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 Years
- Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in Adults
- Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years
- Immunogenicity of a Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Undergoing Hemodialysis
- MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine
- Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses
- Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines
- Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
- Senescent Immunity in Elders and Vaccine Responses (SILVER)
- Systems Investigation of Vaccine Responses in Aging and Frailty